Poly(caprolactone)-modified Pluronic P105 micelles for reversal of paclitaxcel-resistance in SKOV-3 tumors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Poly(caprolactone)-modified Pluronic P105 micelles for reversal of paclitaxcel-resistance in SKOV-3 tumors

Published:2012-06 Issue:18 Volume:33 Page:4741-4751
ISSN:0142-9612
Container-title:Biomaterials
language:en
Short-container-title:Biomaterials

Author:

Wang Yongzhong,Hao Junguo,Li Yajuan,Zhang Zhiwen,Sha Xianyi,Han Limei,Fang Xiaoling

Publisher

Elsevier BV

Subject

Mechanics of Materials,Biomaterials,Biophysics,Ceramics and Composites,Bioengineering

Reference35 articles.

1. Mechanisms of cancer: multidrug resistance;Filipits;Drug Discov Today Dis Mech,2004

2. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators;Krishna;Curr Med Chem Anticancer Agents,2001

3. Evidence for modulation of P-glycoprotein-mediated efflux by methoxypolyethylene glycol-block-polycaprolactone amphiphilic diblock copolymers;Zastre;Pharm Res,2004

4. Liposome-based approaches to overcome anticancer drug resistance;Mamot;Drug Resist Updat,2003

5. Pluronic((R)) block copolymers for overcoming drug resistance in cancer;Kabanov;Adv Drug Deliv Rev,2002

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pluronic modified PLA based hybrid block copolymeric nanoformulation enhanced anti-cancer therapeutic efficacy of Epirubicin;European Polymer Journal;2023-07

2. Quatramer™ encapsulation of dual‐targeted PI3‐Kδ/HDAC6 inhibitor, HSB‐510, suppresses growth of breast cancer;Bioengineering & Translational Medicine;2023-05-12

3. Novel Development of Nanoparticles—A Promising Direction for Precise Tumor Management;Pharmaceutics;2022-12-21

4. Co-encapsulation of PI3-Kδ/HDAC6 dual inhibitor and Navitoclax in Quatramer™ nanoparticles for synergistic effect in ER+ breast cancer;International Journal of Pharmaceutics;2022-11

5. Quatramer™ mediated co-delivery of PI3-Kδ/HDAC6 dual inhibitor augments the anti-cancer efficacy of Epirubicin in breast cancer;European Journal of Pharmaceutics and Biopharmaceutics;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3